Mirati Therapeutics Announces Long-term Survival Results from an Exploratory Analysis of Sitravatinib plus Nivolumab in Patients with Non-squamous Non-Small Cell Lung Cancer Who are Resistant to Checkpoint Inhibitors ...Middle East

SAN DIEGO, Sept. 20, 2021 /PRNewswire/ -- Mirati Therapeutics, Inc. (NASDAQ: MRTX), a clinical-stage targeted oncology company, today announced results from a post hoc exploratory analysis of the Phase 2 study, MRTX-500. Results showed durable responses and long-term survival with...

Hence then, the article about mirati therapeutics announces long term survival results from an exploratory analysis of sitravatinib plus nivolumab in patients with non squamous non small cell lung cancer who are resistant to checkpoint inhibitors was published today ( Monday 20/09/2021 - 03:30 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Mirati Therapeutics Announces Long-term Survival Results from an Exploratory Analysis of Sitravatinib plus Nivolumab in Patients with Non-squamous Non-Small Cell Lung Cancer Who are Resistant to Checkpoint Inhibitors )

Also on site :

• 'Came here in good faith but ... ': JD Vance on why Iran peace talks failed
• Saudi Arabia suspends in-person classes in multiple regions amid heavy rain
• Khoros lance Aurora AI : une nouvelle ère pour la communauté des entreprises